Analyst picks & changes

Rhône-Poulenc Rorer

RPR's presentation of data from its Phase III trial of

Rilutek

(riluzole) to treat amyotrophic lateral sclerosis met with a mixed reception at the American Academy of Neurology meeting, according to Cowen's Lonergan (see Clinical

Read the full 372 word article

How to gain access

Continue reading with a
two-week free trial.